Should Robert Califf gain a second term as US FDA commissioner, he likely will find that many of the issues demanding attention remain the same as when he left the agency five years ago, even though the names of the products now linked with them are different.
As expected, President Biden announced his intention to nominate Califf for FDA commissioner on 12 November. If confirmed, he will become only the second commissioner to serve two non-consecutive terms and the first to gain Senate approval twice.
A swift confirmation could offer Califf several years to address long-standing public health issues as well as affect change at...
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
